# Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

> **NCT00665314** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 5 (actual)

## Conditions studied

- Lymphoma
- Non Hodgkin's Lymphoma
- Hodgkin's Disease
- Multiple Myeloma

## Interventions

- **DRUG:** Plerixafor (AMD3100)
- **DRUG:** Can be any registered nonpegylated form of G-CSF

## Key facts

- **NCT ID:** NCT00665314
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-04
- **Final completion:** 2009-06
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2014-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00665314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00665314, "Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00665314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*